603087.SS
603087.SS
CNE100003ZH1
GAN&LEE PHARMACEUTICALS CO LTD
Loading chart...

Company Profile

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insulin pen needle. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People's Republic of China.

Related stocks

300677.SZ
300677.SZ • China
YKYL
49 CNY
4.8B USD 1Y +33.5%
300896.SZ
300896.SZ • China
IMEIK
95.03 CNY
4.3B USD 1Y -47.3%
603301.SS
603301.SS • China
ZHENDE MEDICAL CO LTD
81 CNY
3.2B USD 1Y +57.8%
688029.SS
688029.SS • China
MICRO-TECH (NANJING) CO LTD
83.3 CNY
2.34B USD 1Y -15.2%
300888.SZ
300888.SZ • China
WINNERMEDICAL
31.36 CNY
2.74B USD 1Y -19.2%
300171.SZ
300171.SZ • China
TOFFLON
15.96 CNY
1.83B USD 1Y +9.2%
300573.SZ
300573.SZ • China
XQYY
35.55 CNY
1.89B USD 1Y -23.3%
2276.HK
2276.HK • China
CONANT OPTICAL
35.6 HKD
2.19B USD 1Y -13.4%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
38.0% p.a.
Max Drawdown (5Y)
-61.3%
Sharpe Ratio (5Y)
-0.10
Beta Factor
0.26
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (38.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -61.3% in the extended horizon.
ende